Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation

Executive Summary

• Red Light Holland and Filament Health have entered into a definitive arrangement agreement whereby Red Light will acquire Filament’s business via a statutory plan of arrangement.
• The transaction will combine Red Light’s large‑scale mushroom production, brand presence and consumer data with Filament’s GMP‑compliant manufacturing facility, Health Canada Level 8 Controlled Substances Dealer’s Licence, FDA‑authorized clinical programs, and 76 patents covering natural psilocybin extraction and formulation.
• Upon completion, existing Red Light shareholders are expected to own ~70% of the combined company; up to 182.4 million consideration shares will be issued to Filament shareholders, with lock‑up and escrow provisions.

Key Details

• Regulatory & Manufacturing Assets: Acquisition adds GMP‑compliant pharma manufacturing, a Health Canada Level 8 Dealer’s Licence, and FDA‑authorized clinical development program to Red Light’s platform.
• Intellectual Property: Filament contributes 76 issued patents across 15 families covering natural psilocybin extraction, purification, stabilization, and delivery formulations.
• Clinical Supply: Filament’s lead botanical candidate PEX010 is currently supplied to >70 global academic/philanthropic research studies and supports compassionate‑use programs.
• Consideration Structure: Each Filament common share will be exchanged for Red Light consideration shares at a price equal to the greater of (i) $0.02 floor, (ii) 10‑day VWAP ending five business days before effective date, or (iii) 10‑day VWAP beginning the first full day after announcement. Expected exchange ratio ≈ 0.0756 (assuming floor price).
• Share Issuance: Up to 182,447,452 consideration shares may be issued (including debt settlement and transaction bonuses). Post‑transaction Red Light share count projected at ~608.2 million; existing Red Light shareholders to hold ~70% of outstanding shares.
• Lock‑up & Escrow: Consideration shares subject to resale restrictions – 50% released after six months, 25% after nine months, remaining 25% after twelve months. Approximately 7.5% of consideration shares will be escrowed for 12 months to secure indemnification obligations.
• Board Representation: One Filament nominee will join Red Light’s board post‑closing.
• Closing Timeline & Conditions: Expected completion in Q2 2026, subject to Filament shareholder approval at a special meeting, regulatory and court approvals, and customary closing conditions. No Red Light shareholder vote required.
• Strategic Rationale: Integration aims to streamline operations, consolidate teams, improve capital efficiency, and create a unified platform for regulated psychedelic drug development, API licensing, clinical‑trial supply partnerships, compassionate‑use programs, and international pharmaceutical distribution.
• Financial Impact: Transaction includes a $500,000 termination/reverse‑termination fee payable under certain breach scenarios; standard representations, warranties, covenants, and non‑solicitation provisions are included.

Notable Quotes

• “This marks a strategic milestone for Red Light as we accelerate our focus on regulated psychedelic medicine and clinical drug development.” – Todd Shapiro, CEO & Director, Red Light Holland.
• “Our Health Canada and FDA‑authorized clinical programs, GMP facility, and Dealer’s Licence provide a strong scientific and regulatory foundation.” – Benjamin Lightburn, CEO & Co‑Founder, Filament Health.